ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

Sponsor
ERX Pharmaceuticals (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04890873
Collaborator
(none)
40
Enrollment
1
Location
2
Arms
11.2
Anticipated Duration (Months)
3.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective is to assess the safety and tolerability of single and multiple oral doses of ERX1000 in obese subjects.

Condition or DiseaseIntervention/TreatmentPhase
Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
ERX1000 - A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity
Actual Study Start Date :
Apr 19, 2021
Anticipated Primary Completion Date :
Mar 25, 2022
Anticipated Study Completion Date :
Mar 25, 2022

Arms and Interventions

ArmIntervention/Treatment
Experimental: ERX1000

ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension Proposed dose level for Part A: 4 mg Proposed dose level for Part B: 4 mg. The dose administered will not exceed the highest dose administered in Part A.

Drug: ERX1000
ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension

Placebo Comparator: Placebo

Reference product: Magnesium hydroxide carbonate powder prepared in an oral suspension

Drug: Placebo
A suspension containing magnesium hydroxide carbonate in polysorbate
Other Names:
  • Magnesium hydroxide carbonate
  • Outcome Measures

    Primary Outcome Measures

    1. Part A (Single Dose Group A9): Incidence and severity of adverse events (AEs) [Day 1 up to end of study (Day 10)]

    2. Part A (Single Dose Group A9): Incidence of clinical laboratory abnormalities [Screening (Day -28) up to end of study (Day 10)]

    3. Part A (Single Dose Group A9): Incidence of 12-lead electrocardiogram (ECG) abnormalities [Screening (Day -28 to Day -2), Days 1, 3 and 10]

    4. Part A (Single Dose Group A9): Incidence of vital sign abnormalities [Screening (Day -28 to Day -2), Check-in (Day -1), Days 1, 3, 4, 5, 6 and 10]

    5. Part A (Single Dose Group A9): Incidence of physical examination abnormalities [Check-in (Day -1), Days 6 and 10]

    6. Part B (Multiple Dose Group B5): Incidence of 12-lead electrocardiogram (ECG) abnormalities [Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 4, 7, 10, 19, 25, 28, 30 and 37]

    7. Part B (Multiple Dose Group B5): Incidence of vital sign abnormalities [Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 19, 22, 25, 28, 30 and 37]

    8. Part B (Multiple Dose Group B5): Incidence of physical examination abnormalities [Check-in (Day -2), Days 30, 33 and 37]

    9. Part B (Multiple Dose Group B6): Incidence of 12-lead electrocardiogram (ECG) abnormalities [Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 4, 7, 10, 19, 25, 30 and 37]

    10. Part B (Multiple Dose Group B6): Incidence of vital sign abnormalities [Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 19, 22, 25, 28, 29, 30 and 37]

    11. Part B (Multiple Dose Group B6): Incidence of physical examination abnormalities [Check-in (Day -2), Days 30, 34 and 37]

    12. Part B (Multiple Dose Group B5 and Multiple Dose Group B6): Incidence and severity of adverse events (AEs) [Day 1 up to end of study (Day 37)]

    13. Part B (Multiple Dose Group B5 and Multiple Dose Group B6): Incidence of clinical laboratory abnormalities [Screening (Day -28) up to end of study (Day 37)]

    Secondary Outcome Measures

    1. Part A (Single Dose Group A9): Plasma pharmacokinetic (PK) outcome endpoint of ERX1000, AUC0-t [Day 1, 8 and 10]

    2. Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, AUC0-∞ [Day 1, 8 and 10]

    3. Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, AUC0-τ [Day 1, 8 and 10]

    4. Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, Cmax [Day 1, 8 and 10]

    5. Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, trough (predose) plasma concentration (Ctrough) [Day 1, 8 and 10]

    6. Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, Tmax [Day 1, 8 and 10]

    7. Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, time of last measurable concentration (tlast) [Day 1, 8 and 10]

    8. Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, t1/2 [Day 1, 8 and 10]

    9. Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, apparent total plasma clearance (CL/F) [Day 1, 8 and 10]

    10. Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, apparent volume of distribution (Vz/F) [Day 1, 8 and 10]

    11. Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, accumulation ratio (AR). [Day 1, 8 and 10]

    12. Part A (Single Dose Group A9): Urine PK outcome endpoint of ERX1000, amount of drug excreted in urine over the sampling period (Aeu) [Day 1]

    13. Part A (Single Dose Group A9): Urine PK outcome endpoint of ERX1000, percentage of dose excreted in urine over the sampling interval (%Feu) [Day 1]

    14. Part A (Single Dose Group A9): Urine PK outcome endpoint of ERX1000, renal clearance (CLR) [Day 1]

    15. Part B (Multiple Dose Group B5): Plasma pharmacokinetic (PK) outcome endpoint of ERX1000, AUC0-t [Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37]

    16. Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, AUC0-∞ [Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37]

    17. Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, AUC0-τ [Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37]

    18. Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, Cmax [Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37]

    19. Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, trough (predose) plasma concentration (Ctrough) [Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37]

    20. Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, Tmax [Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37]

    21. Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, time of last measurable concentration (tlast) [Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37]

    22. Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, t1/2 [Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37]

    23. Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, apparent total plasma clearance (CL/F) [Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37]

    24. Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, apparent volume of distribution (Vz/F) [Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37]

    25. Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, accumulation ratio (AR). [Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37]

    26. Part B (Multiple Dose Group B5): Urine PK outcome endpoint of ERX1000, amount of drug excreted in urine over the sampling period (Aeu) [Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37]

    27. Part B (Multiple Dose Group B5): Urine PK outcome endpoint of ERX1000, percentage of dose excreted in urine over the sampling interval (%Feu) [Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37]

    28. Part B (Multiple Dose Group B5): Urine PK outcome endpoint of ERX1000, renal clearance (CLR) [Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37]

    29. Part B (Multiple Dose Group B6): Plasma pharmacokinetic (PK) outcome endpoint of ERX1000, AUC0-t [Days 1, 7, 13, 19, 25, 31, 32, 34 and 37]

    30. Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, AUC0-∞ [Days 1, 7, 13, 19, 25, 31, 32, 34 and 37]

    31. Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, AUC0-τ [Days 1, 7, 13, 19, 25, 31, 32, 34 and 37]

    32. Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, Cmax [Days 1, 7, 13, 19, 25, 31, 32, 34 and 37]

    33. Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, trough (predose) plasma concentration (Ctrough) [Days 1, 7, 13, 19, 25, 31, 32, 34 and 37]

    34. Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, Tmax [Days 1, 7, 13, 19, 25, 31, 32, 34 and 37]

    35. Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, time of last measurable concentration (tlast) [Days 1, 7, 13, 19, 25, 31, 32, 34 and 37]

    36. Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, t1/2 [Days 1, 7, 13, 19, 25, 31, 32, 34 and 37]

    37. Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, apparent total plasma clearance (CL/F) [Days 1, 7, 13, 19, 25, 31, 32, 34 and 37]

    38. Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, apparent volume of distribution (Vz/F) [Days 1, 7, 13, 19, 25, 31, 32, 34 and 37]

    39. Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, accumulation ratio (AR). [Days 1, 7, 13, 19, 25, 31, 32, 34 and 37]

    40. Part B (Multiple Dose Group B6): Urine PK outcome endpoint of ERX1000, amount of drug excreted in urine over the sampling period (Aeu) [Days 1, 7, 13, 19, 25, 31, 32, 34 and 37]

    41. Part B (Multiple Dose Group B6): Urine PK outcome endpoint of ERX1000, percentage of dose excreted in urine over the sampling interval (%Feu) [Day 1 and Day 25]

    42. Part B (Multiple Dose Group B6): Urine PK outcome endpoint of ERX1000, renal clearance (CLR) [Day 1 and Day 25]

    43. Part B (Multiple Dose Group B5): Pharmacodynamic (PD) outcome endpoint of ERX1000, body weight [Screening (Day -28 to Day -3), Days -1, 8, 15, 22, 28, 30, 33 and 37]

    44. Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum leptin [Days -1, 7, 14, 21, 27 and 30]

    45. Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid - High-density lipoprotein cholesterol (HDL) [Days -1, 14 and 27]

    46. Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid - Low-density lipoprotein cholesterol (LDL) [Days -1, 14 and 27]

    47. Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid -Total cholesterol [Days -1, 14 and 27]

    48. Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid - Triglyceride [Days -1, 14 and 27]

    49. Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum insulin [Days 7 and 21]

    50. Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum glucose [Days -1, 14 and 27]

    51. Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum insulin [Days -1, 14 and 27]

    52. Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, derived from oral glucose tolerance test (OGTT) - Homeostatic Model Assessment of Insulin Resistance [Days -1, 14 and 27]

    53. Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, assessments derived from oral glucose tolerance test (OGTT) - Matsuda Index [Days -1, 14 and 27]

    54. Part B (Multiple Dose Group B6):Pharmacodynamic (PD) outcome endpoint of ERX1000, body weight [Screening (Day -28 to -3), Days -1, 8, 15, 22, 28, 30, 34 and 37]

    55. Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, serum leptin [Day -1, 7, 14, 21, 27 and 30]

    56. Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid - High-density lipoprotein cholesterol (HDL) [Day -1, 14 and 27]

    57. Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid - Low-density lipoprotein cholesterol (LDL) [Day -1, 14 and 27]

    58. Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid -Total cholesterol [Day -1, 14 and 27]

    59. Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid - Triglyceride [Day -1, 14 and 27]

    60. Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, serum insulin [Days 7 and 21]

    61. Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum glucose [Days -1, 14 and 27]

    62. Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum insulin [Days -1, 14 and 27]

    63. Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - Homeostatic Model Assessment of Insulin Resistance [Days -1, 14 and 27]

    64. Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessments derived from oral glucose tolerance test (OGTT) - Matsuda Index [Days -1, 14 and 27]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 55 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions.

    • Adult females and males, of any race, between 18 and 55 years of age, inclusive, at Screening.

    • Females of non-childbearing potential, which is defined as permanently sterile (ie, due to hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), or with bilateral tubal ligation or Essure® (hysteroscopic bilateral tubal occlusion) with confirmation of occlusion of the fallopian tubes performed at least 3 months prior to Screening, or postmenopausal (defined as at least 12 months post cessation of menses without an alternative medical cause and follicle-stimulating hormone [FSH] level

    ≥ 40 mIU/mL). Males will agree to use contraception and refrain from sperm donation.

    • Body mass index between 30.0 and 39.9 kg/m^2, inclusive, at Screening.

    • Glycosylated hemoglobin (HbA1c) level of < 6.5% at Screening (test may be repeated once for confirmation of out-of-range values).

    • Vital signs at Screening and Check-in as per the following ranges and stable (measured in a supine position after a minimum of 5 minutes of rest):

    1. Systolic blood pressure ≥ 90 and ≤ 140 mmHg

    2. Diastolic blood pressure ≥ 50 and ≤ 90 mmHg

    3. Pulse rate ≥ 50 and ≤ 100 bpm

    • In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations at Screening and/or Check-in as assessed by the Investigator (or designee).
    Exclusion Criteria:
    • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks prior to dose administration on Day 1.

    • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).

    • Obesity induced by known endocrine or genetic disorders (eg, Cushing syndrome, hypothyroidism, Prader Willi syndrome).

    • Any previous surgical treatment or procedures with medical devices (such as insertion of lap band or gastric balloons) for obesity (excluding liposuction if performed > 1 year prior to Check-in).

    • History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, which would increase the subject's risk of participation.

    • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair > 6 months prior to Screening will be allowed).

    • History or evidence of underlying liver disease, including viral (hepatitis B and C) or alcoholic hepatitis, or confirmed diagnosis of nonalcoholic steatohepatitis (NASH); nonalcoholic fatty liver disease (NAFLD) with qualifying liver function tests (LFTs) will be allowed.

    • Gilbert's Syndrome (congenital non-hemolytic hyperbilirubinemia) or suspicion of Gilbert's Syndrome based on total and direct bilirubin.

    • Laboratory results that exceed the following thresholds at Screening AND Check-in (laboratory tests may be repeated once for confirmation of out-of-range values) as specified:

    1. alanine aminotransferase (ALT) > 1.5 × upper limit of normal (ULN)

    2. aspartate aminotransferase (AST) > 1.5 × ULN

    3. gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), total bilirubin, or International Normalized Ratio (INR) > ULN

    4. Hemoglobinopathy, hemolytic anemia, or chronic anemia (hemoglobin concentration < 13.0 g/dL [130 g/L] for males, < 11.0 g/dL [110 g/L] for females) at Screening or any other condition known to interfere with interpretation of HbA1c measurement

    5. Neutrophils < 1.5 × 109/L deemed clinically significant by Investigator upon a confirmatory repeat

    6. Thyroid-stimulating hormone (TSH) level above the normal range, confirmed on repeat

    • History or presence of cardiac arrhythmia (at the discretion of the Investigator) or congenital long QT syndrome.

    • A QT interval corrected for heart rate using Fridericia's method (QTcF) > 450 msec for males or > 470 msec for females on Screening ECG. At the discretion of the Investigator, ECG may be repeated twice and an average taken of the 3 readings.

    • The subject has creatinine clearance ≤ 80 mL/minute as calculated using the Cockroft-Gault equation. At the discretion of the Investigator, evaluation may be repeated once to confirm.

    • History of alcoholism or drug/chemical abuse within 2 years prior to Check in.

    • Alcohol consumption of > 14 units per week. One unit of alcohol equals 12 oz (360 mL) of beer, 1½ oz (45 mL) of liquor, or 5 oz (150 mL) of wine.

    • Positive urine drug screen at Screening; or positive alcohol breath test result or positive urine drug screen at Check-in.

    • Positive hepatitis B surface antigen and/or hepatitis C antibody and/or positive human immunodeficiency virus 1/2 (Appendix 2).

    • Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days or 5 half-lives prior to dosing, whichever is longer.

    • Subjects who are actively dieting, have gained or lost > 5 pounds, or using or intend to use any prescription or nonprescription drugs for weight loss including herbal or other dietary supplements within 3 months prior to Check-in.

    • Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to Check-in and throughout the outpatient Follow-up period.

    • Use or intend to use any prescription medications/products within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).

    • Use or intend to use slow-release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).

    • Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 14 days prior to Check-in and throughout the outpatient Follow-up period, unless deemed acceptable by the Investigator (or designee).

    • Consumption of alcohol from 72 hours prior to Check-in.

    • Use of tobacco- or nicotine-containing products (including nicotine and non-nicotine e-cigarettes, vaping, etc.) within 3 months prior to Check-in, or positive cotinine at Screening or Check-in.

    • Receipt of blood products within 2 months prior to Check-in.

    • Donation of blood from 8 weeks prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening.

    • Poor peripheral venous access.

    • Have previously completed or withdrawn from this study or any other study investigating ERX1000, and have previously received the investigational product.

    • Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Covance Clinical Research Unit Inc.MadisonWisconsinUnited States53704

    Sponsors and Collaborators

    • ERX Pharmaceuticals

    Investigators

    • Principal Investigator: Irene Mirkin, MD, Covance

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    ERX Pharmaceuticals
    ClinicalTrials.gov Identifier:
    NCT04890873
    Other Study ID Numbers:
    • ERX1000-C-002
    First Posted:
    May 18, 2021
    Last Update Posted:
    Oct 8, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by ERX Pharmaceuticals
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 8, 2021